ClinicalTrials.gg
Not yet recruitingNCT07886372MG4Updated Oct 21, 2026

Effects of Mango on Insulin Sensitivity in Prediabetes

An interventional study of Mango juice and Control Beverage in Pre Diabetes, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology. Not yet recruiting at 1 site in United States. Open to participants aged 25 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology · Not applicable, Interventional, and Prevention

Updated Oct 21, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
25 Years to 60 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether daily mango consumption for 6 weeks can improve glucose utilization in individuals with prediabetes. The findings from this research may help explore the potential role of mangoes in a healthy diet for people at risk of developing type 2 diabetes

Read the detailed description

The proposed project is based on the hypothesis that mango enhances whole-body insulin sensitivity through increased antioxidant-mediated mechanisms. Accordingly, the primary objective is to explore whole-body insulin sensitivity, as measured by the Matsuda index, in individuals with Pre-DM following 6 weeks of mango consumption. The secondary objective is to clarify the underlying mechanism of action through enhanced antioxidant status. The tertiary object will be to monitor glucose concentration using CGM before and during (the last 10 days of the interventions) to understand the real-time dynamic glucose changes with the mango interventions compared to the control intervention.

This study will last for about six weeks and involves a total of six visits to our Clinical Nutrition Research Center at Illinois Tech (CNRC). These visits include one screening visit to see if you are eligible to participate in this study, followed by Visits 1, 2, 3, 4, and 5. During the study, participant will be asked to drink a mango drink or a simple controlled drink every day for 42 days. Also, they will wear a small device called a continuous glucose monitor (CGM) for a period of 7 days at two different times in the study. This device remains on their skin and tracks their blood sugar level day and night, so we can see how it changes in real time.

Screening Visit:

Participant's eligibility for the study is based on the inclusion and exclusion criteria listed above. To assess this, they will need to arrive at the CNRC fasting for 10-12 hours, meaning no food or drink other than plain water during this period.

During the screening visit, the following assessments will be conducted:

  • The participant will complete a screening questionnaire about their health, dietary habits, and physical activity history.
  • The participant's height, weight, waist circumference, and body composition will be measured. Their Body Mass Index (BMI) will be calculated based on their height and weight. BMI is an estimate of body fat that applies to both adult men and women.
  • The participant's forehead temperature, blood pressure, and heart rate will be measured. They will be seated in a comfortable chair with their feet flat on the ground and uncrossed. They will be asked to relax for five minutes before their blood pressure and heart rate are recorded.
  • A finger prick test will be performed to check their blood sugar levels.
  • A licensed healthcare practitioner (LHCP) and/or a certified phlebotomist will assess their arm veins using a vein access scale test. A butterfly needle will then be used to draw 3 milliliters (mL) of blood from their arm to measure their plasma blood glucose levels.
  • If the participant is a woman under the age of 60 year, they will be required to take a pregnancy test.

Also participants will complete a Food Frequency Log to evaluate their typical consumption patterns for specified food products. For each listed food item, participants will report their intake frequency by selecting one of five response options: more than once per day, once per day, 2-3 times per week, once per week, or not at all.

Based on the results of the questionnaire, blood glucose levels, physical measurements, and overall health evaluation, the participant may meet the eligibility criteria and be invited to participate in the study.

Procedures for Each Study Day Visit (Visits 1, 2, 3, 4 and 5):

VISIT 1: (which may take place on the same day as the screening visit or on a different day)

If participant qualify based on your screening results, visit 1 can take place immediately after your screening or on a later date. This visit lasts approximately 30-45 minutes, during which participant will meet with one of our investigators who will provide detailed instructions on the study procedures and how to prepare for each study day. Participant will also receive training on study procedures, including dietary restrictions, medications, and supplements to avoid, food and GI-tract diary recording, and overnight fasting requirements. Study dates will be scheduled, and participant will receive a study booklet containing the study calendar and all the instructions covered during visit 1.

CGM Placement: During this visit, the study staff will prepare the participant for glucose monitoring. A Continuous Glucose Monitor (CGM) will be placed on participant's arm. This is a small sensor that remains on skin to monitor the blood glucose levels.

Diet restrictions ("Foods to Avoid"): Participant will be asked to continue their usual dietary habits throughout study. However, certain foods and beverages must be avoided, as they may interfere with our ability to assess the effects of mango consumption.

They will be asked to limit their intake of mango, dark chocolate, chestnut, cloves and red wine throughout the study. Additionally, participants will be provided a specific list of foods to avoid for three days prior to each longer study visit (Visits 2 and 5), along with a separate 24-hour avoidance list before those visits.

ASA24 Food Recall: To help track diet, participant will use an online tool called the ASA24 to report all food and beverages consumed during the previous day. They will complete this questionnaire during every single study visit, including Visits 1, 2, 3, 4, and 5. In addition to these visits, they will complete the ASA24 weekly at home to document what they ate the day before. Each questionnaire takes about 45 minutes to finish. To make this easier, they will get regular reminders, so they know exactly when to complete their weekly records.

GI-tract Diary: To help us understand gut, participant will simply answer a few questions about your stomach and digestion by ticking the boxes that best describe how you feel.

Visit 2 and 5: LMTT (Liquid Meal Test)

Participant will be asked to fast for at least 10 hours (no food or drink except plain water). We will collect their initial fasting blood. They will be asked to consume a liquid meal consisting of two bottles of Ensure Original Nutrition Shake. This meal provides 440 kcal, 20 g of sugar, 12 g of fat, and 10 g of protein. To see how their body processes the meal, additional blood samples will be and collected at specific times: one fasting blood draw before the LMTT followed by 15mins, 30mins, 60mins, 90mins, 120mins, 180mins and 240mins after they finish the drink.

At the end of Visit 2, they will be given a 16-day supply of study beverages to take home and consume daily until their next visit.

Before each of the study day visit:

The day before your Study Day Visit, they will review the instructions on "How to Prepare for Your Study Day". This will include guidelines for eating a standardized dinner meal, fasting overnight for at least 10 hours (which aligns with typical overnight fasting). They will also be asked to avoid vigorous physical activity and alcoholic beverages for the 24 hours preceding their study day, aim for their usual night's sleep, and maintain their normal diet except for the specified restrictions under "Foods and Beverages to AVOID or Limit."

3-Day food record: Three days before their Study Days, they will avoid mango, dark chocolate, red wine, almonds, walnuts and pecans. Additionally, they must refrain from consuming caffeinated beverages and alcohol for 24 hours before the Study Day. During this period, they will complete a three-day consecutive food record, documenting everything they eat and drink, including the portion size, from the time they wake up until they go to sleep.

Standardized Meal: The night before Visit 2 and 5, they will eat a repeatable dinner of either a homemade meal or a frozen meal provided to you by CNRC, similar as Visit 1.

ASA24 and GI-tract diary: During your visits, you will use the online links to fill out your ASA24 food record and answer the GI-Track questionnaire about their gut health.

At the end of the Study Days: They will be evaluated for safety and any discomfort or symptoms before leaving and will be given a 16-days supply of study beverages to take home and consume daily until their next visit. They will receive a take-home snack, and compensation will be issued after all study procedures are completed. Additionally, they will be given instructions on how to prepare for their next visit.

How much blood will be collected during the study visit? Blood will be collected a total of eight times on each visit (Visits 2 and 5), for approximately 91 mL of blood collected per visit. Throughout the entire study, a total of approximately 190 mL of blood will be collected.

Visit 3: Pickup Day This is a shorter visit designed to keep the participant supplied for the study. Staff will briefly meet with them to see how they are doing. They will pick up their next 19-days supply of study beverages to last until Visit 4.

ASA24 and GI-tract diary: During visit, they will use the online links to fill out their ASA24 food record and answer the GI-Track questionnaire about gut health.

Visit 4: Pickup visit and Second CGM Placement A new Continuous Glucose Monitor (CGM) sensor will be placed on participant's arm to monitor their glucose levels leading up to their final visit. They will pick up their next 7-days supply of study beverages to last until Visit 5.

ASA24 and GI-tract diary: During their visit, they will use the online links to fill out your ASA24 food record and answer the GI-Track questionnaire about their gut health.

02

Conditions studied

  • Pre Diabetes

Browse trials for

03

In context

Glucose Intolerance

792 studies on the registry are indexed under Glucose Intolerance; 126 are open to participants now.

This study's planned enrollment of 64 is close to the median of 60 across 656 interventional studies indexed under Glucose Intolerance.

Browse Glucose Intolerance studies →

Lead sponsor

Clinical Nutrition Research Center, Illinois Institute of Technology is the lead sponsor of 61 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be between 25-60 years old.
  • Have a BMI of 25-35 kilograms per square meter.
  • Have fasting blood glucose between 100-125 milligrams per deciliter or Glycated hemoglobin (HbA1c) between 5.7-6.4%.
  • Be non-smokers for at least 12 months.
  • Be generally healthy, with no major organ-related diseases.
  • Not take medications or supplements that could interfere with the study.
  • Be able to follow study procedures, including dietary restrictions and scheduled visits.

Exclusion criteria

Exclusion Criteria:

  • Smoke, vape, or use marijuana.
  • Have allergies or intolerance to mangoes or study foods.
  • Have blood pressure above 160/100 millimeters of Mercury.
  • Have fasting blood glucose above 125 milligrams per deciliter.
  • Have a history of major heart disease, stroke, or cancer in the past five years.
  • Be pregnant, planning to become pregnant, or breastfeeding.
  • Take anti-inflammatory drugs or certain dietary supplements.
  • Have had major surgery or trauma in the past two months.
  • Follow extreme diets (e.g., vegan, Atkins).
  • Have used antibiotics in the last six weeks.
  • Have a history of eating disorders or substance abuse in the past two years.
  • Drink more than three cups of coffee or tea per day.
  • Have donated blood in the last three months.
  • Be professional athletes or do excessive exercise.
  • Have had weight changes of more than 11 pounds in the past two months.
  • Work overnight shifts.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Mango beverage

    1 cup (165 grams) of mango smoothie twice a day.

    Other: Mango juice

  • Placebo comparator
    Control (no mango)

    calorie-matched control intervention

    Other: Control Beverage

Interventions

  • OtherMango juice

    Mango beverage

  • OtherControl Beverage

    Italian Ice beverage

06

What researchers measure

Primary outcomes

  1. Fasting Plasma Glucose Concentration

    Fasting plasma glucose concentration will be measured in plasma samples using a Randox automated clinical analyzer.

    Time frame: Baseline and Week 6

  2. Fasting Plasma Insulin Concentration

    Fasting plasma insulin concentration will be measured in plasma samples using a Randox automated clinical analyzer.

    Time frame: Baseline and Week 6

  3. Insulin Sensitivity

    The Matsuda index for insulin sensitivity will be calculated using validated equations based on paired glucose and insulin values obtained during the Liquid Meal Tolerance Test (LMTT).

    Time frame: Baseline and Week 6

Secondary outcomes

  1. Plasma Glutathione Peroxidase Activity

    Plasma glutathione peroxidase activity will be measured to assess systemic antioxidant enzyme activity before and after the intervention.

    Time frame: Baseline and Week 6

  2. Plasma Superoxide Dismutase Activity

    Plasma superoxide dismutase activity will be measured to assess systemic antioxidant enzyme activity before and after the intervention.

    Time frame: Baseline and Week 6

  3. Expression of Nrf-2 Pathway Genes

    Relative expression of target genes (Nrf-2, glutathione peroxidase 2 \[GLx2\], glutathione S-transferase \[GST\], and NAD(P)H:quinone oxidoreductase-1 \[NQO1\]) will be quantified from blood collected in Paxgene tubes using qPCR.

    Time frame: Baseline and Week 6

  4. Continuous Glucose Monitoring (CGM)

    Interstitial glucose profiles will be captured using a continuous glucose monitor worn for 7-days before the LMTT.

    Time frame: 7-day monitoring periods at baseline and Week 6

  5. Fasting Plasma Triglyceride Concentration

    Fasting plasma triglyceride concentration will be measured in plasma samples using a Randox automated clinical analyzer.

    Time frame: Baseline and Week 6

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07886372
Collaborators
National Mango Board
Responsible party
Sponsor
First posted
Oct 21, 2026
Start date
Oct 28, 2026 (estimated)
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 29, 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Indika Edirisinghe, PhD
Contact
iedirisi@illinoistech.edu
708-308-0178
Chelsea Preiss, M.S.
Contact
cpreiss@illinoistech.edu
312-567-5300
Britt Burton-Freeman, PhD
principal investigator · Illinois Institute of Technology
Amandeep Sandhu, PhD
principal investigator · Illinois Institute of Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion